started · updated
GLP-1 and SGLT-2 medications show potential in slowing kidney disease
Research published in the British Medical Journal (BMJ) indicates that GLP-1 receptor agonists, such as semaglutide and liraglutide, and SGLT-2 inhibitors may provide significant protection against kidney disease. The BESTMED study, which analyzed data from 75,455 adults over a median of 32 months, found that these medications can slow renal decline compared to traditional therapies.
The therapeutic benefit is particularly notable in patients with urinary albumin levels above 30 mg/g of creatinine. In this specific group, the five-year risk of severe renal deterioration dropped to 3.2% for those using GLP-1 or SGLT-2 inhibitors, compared to 5.4% for those using DPP-4 inhibitors, representing a relative risk reduction of 40%.
However, the rapid rise of these weight-loss medications has raised medical concerns. A study published in the journal Obesity revealed that between 2021 and 2025, over one million adults in the United States were prescribed GLP-1 drugs without clear medical necessity in their electronic health records. Experts warn that the use of these injections by individuals with normal body mass indices, often without medical supervision, poses serious health risks.